Dry Eye Disease: Challenges, Treatment Adherence, and Emerging Therapies

Overview

Dry eye disease (DED) presents significant challenges in diagnosis and management, with high rates of treatment discontinuation and patient dissatisfaction. Recent advances in FDA-approved therapies and a personalized, empathetic approach to care are essential to improve patient adherence and outcomes.

Background

DED is a chronic condition characterized by tear deficiency leading to ocular surface inflammation, nerve damage, and reduced lacrimal function. It affects millions worldwide and significantly impairs quality of life, including work productivity and daily activities. Despite available treatments, up to 90% of patients discontinue initial medications within a year, often due to limited efficacy and side effects. Emotional and psychological burdens further complicate management, underscoring the need for comprehensive care.

Data Highlights

Key Findings

• High treatment discontinuation rates (90% within one year) contribute to chronic and progressive DED.
• DED symptoms extend beyond physical discomfort, impacting emotional wellbeing and daily functioning.
• Less than 10% of diagnosed patients receive prescription treatments, and only 13% feel their condition is well-managed.
• New FDA-approved therapies, including acoltremon (Tryptyr), offer additional options for individualized care.
• Effective management requires personalized treatment plans, strong physician-patient communication, and consistent follow-up.
• Staff involvement in patient education and support is critical to improve adherence and treatment satisfaction.

Clinical Implications

Clinicians should adopt a holistic, patient-centered approach that addresses both physical symptoms and emotional impacts of DED. Tailoring treatments to patient needs and maintaining open communication can enhance adherence and outcomes. Incorporating new FDA-approved therapies expands options for individualized care, while staff support reinforces education and follow-up.

Conclusion

Managing dry eye disease effectively demands a comprehensive strategy that combines emerging pharmacologic options with empathetic, personalized care. This approach can reduce patient frustration, improve adherence, and ultimately enhance quality of life for those affected.

References

1. Farid M, 2024 -- Dry Eye Disease: The Vicious Cycle of Frustration and Search for Relief
2. Mbagwu M et al., 2024 -- Characterization of discontinuation and switching patterns of dry eye disease medications
3. Chronic Dry Eye Survey, 2021 -- Patient perspectives on chronic dry eye management